Draft · 6 min read
Brain fog in perimenopause is not a mystery
It is a measurable hormonal shift, and there is a clinical answer for it.
When women say "brain fog," they usually mean something specific: a word that won't arrive, losing the thread of a sentence mid-way through it, walking into a room and standing there. Recall that used to be automatic now takes effort. It is unsettling precisely because it is subtle — nothing is obviously wrong, and yet something clearly is.
For a long time, the clinical response to that complaint was reassurance without evidence. That is no longer the honest answer. One of the largest longitudinal studies of midlife women — the SWAN cohort, which followed more than 2,300 women with repeated cognitive testing — found that the expected improvement from taking a test more than once simply did not occur during the perimenopausal window, then resumed afterwards (Greendale et al., Neurology, 2009). In other words, the change is measurable on objective testing, not just perceived. It is also time-limited.
The pattern has a shape. A clinical review by Maki and Jaff (Climacteric, 2022) puts the number at roughly two-thirds of women reporting cognitive difficulty across the transition, with objective testing showing modest, transient decrements concentrated in verbal memory and attention. "Modest and transient" matters. This is not early decline. It is a window.
What is happening physiologically is a hormonal transition, not a personality change and not a psychiatric one. Oestrogen receptors are distributed through brain regions involved in verbal memory and attention, and the perimenopausal years are defined by hormonal variability — not a smooth decline, but fluctuation. The cognitive complaint tracks that variability.
So what can actually be done? First, name it accurately: measurable, time-limited, and concentrated in specific domains. Second, support what is supportable. Stress physiology is a real amplifier here — cortisol load and poor sleep deepen the subjective fog, and both are modifiable. That is the reasoning behind the formula's structure: standardised ashwagandha root at the dose used in the cortisol trials (Chandrasekhar et al., 2012), rhodiola for mental fatigue and sustained attention (Olsson et al., 2009), and a micronutrient layer beneath the botanicals.
And third, hold a reasonable timeline. Botanicals work on weeks, not days. If nothing has changed by ninety days of consistent use, that is real information too — and worth a conversation with a clinician who takes the complaint seriously.
